ANAVEON AG
Biotechnology ResearchBasel, Switzerland11-50 Employees
A start up based in Switzerland that develops biologics to modulate the functions of cytokines and provide substantial therapeutic benefits to cancer patients.
New Product Launch ANAVEON AG recently launched ANV419 in the OMNIA-2 study, showing their commitment to innovation and expanding their product portfolio in immuno-oncology. This presents an opportunity for collaborative partnerships and potential sales with healthcare providers and institutions looking for advanced cancer treatments.
Strategic Hiring With the appointment of Dr. Eduard Gasal as Chief Medical Officer, ANAVEON AG demonstrates a focus on strengthening their leadership team with clinical expertise. Leveraging this key personnel addition can open doors for business development professionals to engage in discussions with key opinion leaders and medical institutions seeking cutting-edge therapies for cancer.
Therapeutic Development ANAVEON AG's dedication to developing therapies for less immunogenic tumors, along with the success of ANV419, showcases their commitment to addressing unmet medical needs in oncology. This presents an opportunity for sales development representatives to engage with oncologists and healthcare providers seeking innovative solutions for challenging patient cases.
Market Expansion The market trend of expanding therapeutic potential by delivering IL-2 agonists to tumor fighting cells aligns with ANAVEON AG's strategy. Sales professionals can leverage this trend to position ANAVEON's offerings as part of the growing landscape of personalized and targeted therapies, appealing to healthcare providers looking for precision medicine solutions in oncology.
Funding Strength With a funding of $120 million and revenue in the range of $0-10 million, ANAVEON AG exhibits financial stability and growth potential. Business development professionals can utilize this information to build confidence in potential partners, investors, and customers, highlighting the company's ability to deliver long-term value and sustain impactful research and development efforts.
ANAVEON AG uses 8 technology products and services including Google Font API, TweenMax, Open Graph, and more. Explore ANAVEON AG's tech stack below.
ANAVEON AG Email Formats | Percentage |
First.Last@anaveon.com | 49% |
First.MiddleLast@anaveon.com | 1% |
First.Middle@anaveon.com | 1% |
First.Last@anaveon.com | 49% |
Biotechnology ResearchBasel, Switzerland11-50 Employees
A start up based in Switzerland that develops biologics to modulate the functions of cytokines and provide substantial therapeutic benefits to cancer patients.
ANAVEON AG has raised a total of $120M of funding over 2 rounds. Their latest funding round was raised on Dec 16, 2021 in the amount of $120M.
ANAVEON AG's revenue is in the range of $10M
ANAVEON AG has raised a total of $120M of funding over 2 rounds. Their latest funding round was raised on Dec 16, 2021 in the amount of $120M.
ANAVEON AG's revenue is in the range of $10M